Yifang Biopharmaceutical: D-2570 has been approved to conduct phase II clinical trials for psoriasis in the United States.

Yifang Biology announces that the Phase II clinical trial application for D-2570 monotherapy for psoriasis submitted to the US Food and Drug Administration has reached the 30-day default period recently, and no objections have been received from the FDA. According to relevant regulations, the Phase II clinical trial of D-2570 for monotherapy of Psoriasis in the United States has officially been approved.